TOKYO/CAMBRIDGE - The U.S. Food and Drug Administration has accepted Eisai’s application for a subcutaneous autoinjector version of its Alzheimer’s treatment lecanemab-irmb (LEQEMBI) under priority ...
Richmond, VA, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Kaléo, a global leader in drug-delivery device technology and auto-injectors, today announced the appointment of Ram Halthore as Vice President, ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The development process for the ...
Sempresto, Inc., a medical device company pioneering smartphone integrated rescue drug delivery, today announced the acquisition of Alerje’s mobile device integrated auto-injector platform, including ...
MannKind Corporation delivered strong Q3 '25 results, beating EPS and revenue estimates, and shares have responded positively. The FDA accepted the supplemental New Drug Application for the FUROSCIX ...
Offers no-hassle, free virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is available to eligible patients who may ...
Women's Health may earn commission from the links on this page, but we only feature products we believe in. Why Trust Us? An at-home corticosteroid injection that can be used to treat angry, inflammed ...
The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and cluster headaches in adults, Amneal Pharmaceuticals announced Thursday. The ...
The Alzheimer's treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on November 7, 2023. The medicine is now available in a self-injecting pen, Leqembi Iqlik. Credit - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results